title: [The Jervell and Lange-Nielsen syndrome. Natural history, molecular basis and clinical outcome].
abstract: Data on the Jervell and Lange-Nielsen syndrome (JLN), the long QT syndrome (LQTS) variant associated with deafness and caused by homozygous or compound heterozygous mutations on the KCNQ1 or on the KCNE1 genes encoding the IKs current, are still largely based on case reports. We analyzed data from 186 JLN patients obtained from the literature (31%) and from individual physicians (69%). Most patients (86%) had cardiac events and 50% were symptomatic already by age 3. Their QTc was markedly prolonged (557 +/- 65 ms). Most of the arrhythmic events (95%) were triggered by emotions or exercise. Females are at lower risk for cardiac arrest and sudden death (CA/SD). A QTc>550 ms and history of syncope during the first year of life are independent predictors of subsequent CA/SD. Most mutations (90.5%) are on the KCNQ1 gene; mutations on the KCNE1 gene are associated with a more benign course. beta-blockers have only partial efficacy as 51% of the patients had events despite therapy and 29% had CA/SD.
  
  
  CONCLUSIONS
  JLN syndrome is a most severe variant of LQTS, with a very early onset, major QTc prolongation, and is not well responsive to beta-blockers. Subgroups at relatively lower risk for CA/SD are identifiable and include females, patients with a QTc pound550 ms, without events in the first year of life, and with mutations on KCNE1. Early therapy with ICDs has to be considered.
authors.affiliation: Service de cardiologie, Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris. isabelle.denjoy@lrb.aphp.fr
authors.forename: I
authors.initials: I
authors.lastname: Denjoy
authors.forename: J-M
authors.initials: JM
authors.lastname: Lupoglazoff
authors.forename: E
authors.initials: E
authors.lastname: Villain
authors.forename: G
authors.initials: G
authors.lastname: Vaksmann
authors.forename: F
authors.initials: F
authors.lastname: Godart
authors.forename: V
authors.initials: V
authors.lastname: Lucet
authors.forename: A
authors.initials: A
authors.lastname: Leenhardt
authors.forename: P
authors.initials: P
authors.lastname: Guicheney
authors.forename: P
authors.initials: P
authors.lastname: Schwartz
mesh_terms: D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D016757:Death, Sudden, Cardiac / Q000209:etiology; D004562:Electrocardiography; D004644:Emotions; D015444:Exercise / Q000502:physiology; D005260:Female; D006323:Heart Arrest / Q000209:etiology; D006801:Humans; D007223:Infant; D029593:Jervell-Lange Nielsen Syndrome / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D051657:KCNQ1 Potassium Channel / Q000235:genetics; D008297:Male; D009154:Mutation / Q000235:genetics; D024642:Potassium Channels, Voltage-Gated / Q000235:genetics; D012189:Retrospective Studies; D012737:Sex Factors; D013575:Syncope / Q000209:etiology
chemical_list: D000319:Adrenergic beta-Antagonists; C489622:KCNE1 protein, human; D051657:KCNQ1 Potassium Channel; C496909:KCNQ1 protein, human; D024642:Potassium Channels, Voltage-Gated